Prior to ASCO, most interest in Keytruda in mCRPC and aNSCLC
Posted on

Prior to ASCO, Breaking Data asked 30 oncologists to rate each abstract in terms of their level of interest. The chart depicts pre-ASCO oncologist interest in the data. Data regarding KEYTRUDA® in mCRPC and aNSCLC (Keynote 199, Keynote 042 and Keynote 407) generated the most interest. Oncologists were also interested in the OPDIVO® update for stage III/IV melanoma (CheckMate 238).

ABSTRACTS:

PROSTATE | KEYNOTE-199: Pembrolizumab  for docetaxel-ref metastatic castration-resistant prostate cancer

LUNG | KEYNOTE-042: Pembro vs platinum-based chemo as 1L therapy for advanced NSCLC with a PD-L1 tumor proportion score ≥1%: Open-label, phase 3

LUNG | KEYNOTE-407: Phase 3: carbo plus paclitaxel or nab-paclitaxel ± pembrolizumab for patients with metastatic squamous NSCLC

MELANOMA | CheckMate 238: Adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase III trial

LUNG | IMpower131: Primary PFS and safety analysis of a randomized phase 3 study of atezolizumab + carbo + pac or nab-pac vs carbo + nab-pac in 1L advanced squamous NSCLC

BREAST | SANDPIPER: Phase 3 study of taselisib + fulvestrant vs fulvestrant in patients with ER-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer

RET-altered Cancers | phase 1: LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers

BREAST | MONALEESA-3: Ribociclib + fulvestrant in postmenopausal women with HR+, HER2– advanced breast cancer


Source: Breaking Data: 2018 American Society of Oncology (ASCO) Impact Analysis Report: Solid Tumors

advanced non-small cell lung cancer (aNSCLC)

docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)

Quote Icon
First time that immunotherapy is used in prostate cancer, wondering how effective it will be. -Community Oncologist